Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
A Pralsetinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pralsetinib, including repackagers and relabelers. The FDA regulates Pralsetinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pralsetinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pralsetinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pralsetinib supplier is an individual or a company that provides Pralsetinib active pharmaceutical ingredient (API) or Pralsetinib finished formulations upon request. The Pralsetinib suppliers may include Pralsetinib API manufacturers, exporters, distributors and traders.
click here to find a list of Pralsetinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pralsetinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Pralsetinib active pharmaceutical ingredient (API) in detail. Different forms of Pralsetinib DMFs exist exist since differing nations have different regulations, such as Pralsetinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pralsetinib DMF submitted to regulatory agencies in the US is known as a USDMF. Pralsetinib USDMF includes data on Pralsetinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pralsetinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pralsetinib suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pralsetinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pralsetinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pralsetinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pralsetinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pralsetinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pralsetinib suppliers with NDC on PharmaCompass.
Pralsetinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pralsetinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pralsetinib GMP manufacturer or Pralsetinib GMP API supplier for your needs.
A Pralsetinib CoA (Certificate of Analysis) is a formal document that attests to Pralsetinib's compliance with Pralsetinib specifications and serves as a tool for batch-level quality control.
Pralsetinib CoA mostly includes findings from lab analyses of a specific batch. For each Pralsetinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pralsetinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Pralsetinib EP), Pralsetinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pralsetinib USP).
LOOKING FOR A SUPPLIER?
